Skip to content
Atlas Research Compounds

Repair & matrix

GHK-Cu

A copper-binding tripeptide complex studied in matrix biology.

Evidence
Mixed translational
Literature
Laboratory and applied research
Family
Copper-binding tripeptide

Overview

GHK-Cu is investigated in extracellular-matrix remodeling, cell signaling, and skin-related models. The literature includes laboratory and applied contexts, but formulation, exposure, and endpoint differences complicate broad conclusions.

Evidence maturity

Evidence score3/5

Developing clinical evidence

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Mechanism summary

Investigated in copper-dependent signaling, extracellular-matrix remodeling, and cell migration models.

Research category
Cellular Health Research
Editorial status
Published

Evidence synthesis

Structured evidence summary

Human studies
0
Animal studies
7
In vitro records
4
Review records
6
Abstract extracted
7
Metadata verified
10

Evidence strength

Preclinical

Confidence

Low confidence

Major findings

  • The verified set includes matrix biology, fibroblast, wound, pulmonary, skin, skeletal-muscle, and GHK-Cu review records.
  • The strongest catalog framing is copper-binding peptide research with matrix and repair-model context.

Major limitations

  • Human primary-study coverage remains limited in the current verified set.
  • Formulation, exposure, species, and delivery context are major unresolved interpretation boundaries.

Counts are generated from verified PubMed records. Findings above are evidence-map observations, not clinical recommendations or inferred study outcomes. See the scoring methodology.

Scoring methodology

Evidence strength, quality, and confidence

Evidence strength

Compound-level strength is based on the verified study mix: human records, animal records, review or synthesis records, and extraction depth. It describes evidence maturity only.

Study quality

Study-level quality is not assessed for metadata-only records. Abstract-extracted records are rated from study design and extraction depth, not from unreviewed full-text claims.

Confidence

Confidence is capped when records remain metadata verified. Atlas does not raise confidence by counting citations without extracting endpoints, comparators, duration, and limitations.

Workflow states are `METADATA_VERIFIED`, `ABSTRACT_EXTRACTED`, `FULLTEXT_REVIEWED`, and `EDITORIAL_APPROVED`. Because full-text review is not available in this phase, no study is promoted to full-text or editorial-approved status.

Research timeline

Evidence stages describe maturity, not a chronological promise of development.

  1. Identity and target

    Documented

    The compound identity or proposed target is described in research literature.

  2. Preclinical research

    Documented

    Laboratory or animal research forms part of the evidence base.

  3. Human research

    Emerging

    Some human research exists, but scope or maturity remains limited.

  4. Independent synthesis

    Emerging

    Independent replication and synthesis remain important evidence gaps.

Open research questions

  1. 01Which effects require copper coordination?
  2. 02How do formulation and delivery alter bioavailability?
  3. 03Which matrix effects translate beyond in vitro systems?

Literature starting points

These links support further review; inclusion is not an endorsement of every indexed conclusion.

  1. 01

    GHK-Cu literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source

Phase 2 study database

17 verified publications

Search all studies →
2025Topically applied GHK as an anti-wrinkle peptide: advantages, problems, and prospects.Grade D2024The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6Grade C2024Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitroGrade D2023Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.Grade D2023Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.Grade D

Deep research cluster

Explore GHK-Cu by evidence question

MechanismMechanistic pathways reported in verified publications, separated from clinical inference.Human studiesVerified human publications, study designs, findings, and explicit limitations.Animal studiesPreclinical animal models and the boundaries on translating their results.Safety evidenceWhat the verified publication set can and cannot establish about safety.Research historyA publication timeline built only from verified study records.ComparisonsContextual links to related compounds and existing structured comparisons.

Related comparisons

GHK-Cu vs. BPC-157GHK-Cu vs. TA1GHK-Cu vs. TB-500GHK-Cu vs. NAD+GHK-Cu vs. SS-31GHK-Cu vs. MOTS-CBPC-157 vs. GHK-CuTB-500 vs. GHK-CuMOTS-C vs. GHK-CuSS-31 vs. GHK-CuNAD+ vs. GHK-Cu

Continue the research map

Related content

CompoundBPC-157CompoundThymosin Alpha 1CompoundTB-500Verified studyTopically applied GHK as an anti-wrinkle peptide: advantages, problems, and prospects.Verified studyThe glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6Verified studyGlycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitroComparisonGHK-Cu vs. BPC-157ComparisonGHK-Cu vs. TA1ComparisonGHK-Cu vs. TB-500ComparisonGHK-Cu vs. NAD+ComparisonGHK-Cu vs. SS-31ComparisonGHK-Cu vs. MOTS-CComparisonBPC-157 vs. GHK-CuComparisonTB-500 vs. GHK-CuComparisonMOTS-C vs. GHK-CuComparisonSS-31 vs. GHK-CuComparisonNAD+ vs. GHK-CuTopic hubLongevityTopic hubRecoveryTopic hubImmune FunctionTopic hubMitochondrial HealthTopic hubHealthy AgingTopic hubPeptide Research